Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity.
One of the best examples of the renaissance of Src as an open door to cancer has been the demonstration that just five min of Src activation is sufficient for transformation and also for induction and maintenance of cancer stem cells [1]. Many tyrosine kinase receptors, through the binding of their ligands, become the keys that unlock the structure of Src and activate its oncogenic transduction pathways. Furthermore, intracellular isoforms of these receptors, devoid of any tyrosine kinase activity, still retain the ability to unlock Src. This has been shown with a truncated isoform of KIT (tr-KIT) and a truncated isoform of VEGFR-1 (i21-VEGFR-1), which are intracellular and require no ligand binding, but are nonetheless able to activate Src and induce cell migration and invasion of cancer cells. Expression of the i21-VEGFR-1 is upregulated by the Notch signaling pathway and repressed by miR-200c and retinoic acid in breast cancer cells. Both Notch inhibitors and retinoic acid have been proposed as potential therapies for invasive breast cancer.
Laboratori de Genètica Molecular, Universitat de Barcelona, IDIBAPS. Casanova 143, 08036 Barcelona, Spain. belenmezquita@ub.edu.
Belén
B
Mezquita
Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Josep Trueta, s/n 08195 Sant Cugat del Vallès, Spain. pmezquita@uic.es.
Pau
P
Mezquita
Laboratori de Genètica Molecular, Universitat de Barcelona, IDIBAPS. Casanova 143, 08036 Barcelona, Spain. montserrat.pau@gmail.com.
Montserrat
M
Pau
Laboratori de Genètica Molecular, Universitat de Barcelona, IDIBAPS. Casanova 143, 08036 Barcelona, Spain. jmezquita@ub.edu.
Jovita
J
Mezquita
Laboratori de Genètica Molecular, Universitat de Barcelona, IDIBAPS. Casanova 143, 08036 Barcelona, Spain. cmezquita@ub.edu.
Cristóbal
C
Mezquita